Entecavir for Subjects With Chronic Hepatitis B Infection: An Early Access Program
- Conditions
- Hepatitis BChronic Disease
- Registration Number
- NCT00096811
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this clinical research study is to provide entecavir to subjects with chronic Hepatitis B infection who have failed or who have demonstrated intolerance of marketed therapies or for those in whom use of these agents is contraindicated and that have no other available treatment options.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- Hepatitis B Early Access Program
Exclusion Criteria
Not provided
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of entecavir make it effective for chronic hepatitis B patients with lamivudine resistance?
How does entecavir compare to tenofovir in treating chronic hepatitis B patients with prior nucleoside analog failure?
Which biomarkers correlate with sustained virological response to entecavir in HBeAg-positive chronic hepatitis B patients?
What are the long-term safety profiles and management strategies for entecavir in expanded access programs for chronic hepatitis B?
What combination therapies involving entecavir are being explored for HBeAg-negative chronic hepatitis B patients with advanced liver disease?
Trial Locations
- Locations (1)
Local Institution
🇮🇱Zefat, Israel
Local Institution🇮🇱Zefat, Israel